RxDoctor Payments Data

Stuart Waldstreicher, MD

Gastroenterology · Stamford, CTNPI 1114913894

Payments from drug & device makers

$5,111in general payments, 2019–2025

Across 273 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$792
  • Pfizer$741
  • Johnson & Johnson$589
  • Takeda Pharmaceuticals U.S.A., Inc.$287
  • Ardelyx, Inc.$248
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$5,105100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,111 in reported general payments places this provider in the 60th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$130,554
Medicare patients
505
Services billed
1,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab14$394,473
CreonLipase/Protease/Amylase15$35,625
ClenpiqSod Picosulf/Mag Ox/Citric Ac131$22,710
LinzessLinaclotide22$19,857
Mesalamine57$16,957
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C52$7,493
Dexlansoprazole DrDexlansoprazole18$6,929
Sucralfate37$6,584
Balsalazide Disodium28$4,419
Omeprazole239$3,764
Ursodiol18$2,715
SutabSod Sulf/Pot Chloride/Mag Sulf15$2,471
Famotidine137$2,115
Mesalamine ErMesalamine13$1,778
Pantoprazole Sodium74$1,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$589$394,47314 claims
AbbVieCreon, Linzess$1,262$55,48237 claims
Ferring Pharmaceuticals Inc.Clenpiq$118$22,710131 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$792$7,49352 claims
Braintree Laboratories, Inc.Sutab$90$2,47115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Stamford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →